Conflict of interest: P.A. and E.N. have received research funding from Novartis.
Does iron overload really matter in stem cell transplantation?†
Version of Record online: 4 APR 2012
Copyright © 2012 Wiley Periodicals, Inc.
American Journal of Hematology
Volume 87, Issue 6, pages 569–572, June 2012
How to Cite
Armand, P., Sainvil, M.-M., Kim, H. T., Rhodes, J., Cutler, C., Ho, V. T., Koreth, J., Alyea, E. P., Neufeld, E. J., Kwong, R. Y., Soiffer, R. J. and Antin, J. H. (2012), Does iron overload really matter in stem cell transplantation?. Am. J. Hematol., 87: 569–572. doi: 10.1002/ajh.23188
- Issue online: 21 MAY 2012
- Version of Record online: 4 APR 2012
- Accepted manuscript online: 12 MAR 2012 05:07AM EST
- Manuscript Accepted: 28 FEB 2012
- Manuscript Revised: 18 FEB 2012
- Manuscript Received: 29 JAN 2012
- Novartis Oncology and the National Institutes of Health. Grant Number: CA142106-06
- Leukemia and Lymphoma Society (Special Fellowship in Clinical Research)
- Conquer Cancer/ASCO Foundation (Career Development Award)
- American Society of Hematology (Scholar Award)
- 6Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Br J Haematol 2009; 146: 310–316., , , et al.
- 11Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation. Leuk Res 2009; 34: 723–727., , , et al.
- 15Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 2007; 110: 1303–1306., , , et al.